Clinical trials: Diabetes Complication
Retinopathy, Diabetic
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
The purpose of this study is to characterize the systemic and ocular safety and tolerability, pharmacokinetics, exploratory efficacy and pharmacodynamics of 3 months of repeat administration of oral darapladib in diabetic macular…
- Trial name
- NCT01506895
- Testing
- darapladib
- Where
- 16 sites in Australia, Denmark and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcer
A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers
This prospective case series is to gain additional clinical experience in the treatment of diabetic foot ulcers, by documenting and relating patient history (including baseline wound characteristics) and clinical outcomes…
- Trial name
- NCT02799121
- Testing
- ReGenerCell™ Autologous Cell Harvesting Device
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Avita Medical
Diabetic Neuropathies
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to diabetic peripheral neuropathy.
- Trial name
- NCT00380913
- Testing
- Cesamet™ (nabilone)
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- NEMA Research, Inc.
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Olmesartan Medoxomil and Diabetic Nephropathy
Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Proteinuria, Renal Disease
- Trial name
- NCT00362960
- Testing
- Olmesartan medoxomil, Losartan
- Where
- 27 sites in Czechia, Estonia and 5 more
- Volunteers
- 300 people
- Sponsor
- Sankyo Pharma Gmbh
Diabetic Nephropathy
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting…
- Trial name
- NCT03804879
- Testing
- Nidufexor, Standard of Care (SoC)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2…
- Trial name
- NCT07275788
- Testing
- REGEND003
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Regend Therapeutics
Painful Diabetic Neuropathy
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
The primary objective of the trial is to assess the tolerability and safety of long-term SPM 927 administration in subjects with diabetic neuropathy.
- Trial name
- NCT00861042
- Testing
- SPM927/Lacosamide
- Volunteers
- 69 people
- Sponsor
- UCB Pharma
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
- Trial name
- NCT01549769
- Testing
- Bardoxolone Methyl
- Volunteers
- 24 people
- Sponsor
- Biogen
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Diabetes Mellitus, Type 2, Albuminuria
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and…
- Trial name
- CANVAS-R (NCT01989754)
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 341 sites in United States, Argentina and 23 more
- Volunteers
- 5,813 people
- Sponsor
- Janssen Research & Development, LLC
Hypertension, Diabetic Nephropathy
Antiproteinuric Effect of Valsartan and Lisinopril
Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up.
- Trial name
- NCT00171574
- Testing
- Valsartan, Valsartan plus HCTZ, Lisinopril
- Where
- Switzerland
- Volunteers
- 124 people
- Sponsor
- Novartis
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Painful Diabetic Neuropathies
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
- Trial name
- NCT01475786
- Testing
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202)
- Where
- 17 sites in United States, South Korea
- Volunteers
- 104 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Nephropathy
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy.
- Trial name
- NCT00734253
- Testing
- Pyridoxamine Dihydrochloride
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- NephroGenex, Inc.
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetic Foot, Diabetic Foot Ulcer
Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200
Purpose of this phase 1/2a study is to assess the safety and efficacy of administration of allogeneic human oral mucosal stem cells (hOMSCs) in patients suffering from chronic diabetic foot ulcers (DFU).
- Conditions
- Diabetic Foot, Diabetic Foot Ulcer, Diabetic Foot Ulcer Neuropathic
- Trial name
- NCT06003530
- Testing
- hOMSC200
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Cytora Ltd.
Diabetic Retinopathy, Diabetic Macular Edema
Assessment of Retinal Fundus Imaging Camera
The goal of this prospective study is to evaluate device performance when using fundus images taken from retinal fundus cameras in subjects with and without diabetic retinopathy per ETDRS level 35 and higher with or without…
- Trial name
- NCT06173232
- Testing
- Camera Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Digital Diagnostics, Inc.
Diabetic Foot Ulcer (DFU)
A Study Comparing an Investigational Wound Gel With Standard Treatment for Mild to Moderate Diabetic Foot Ulcers
The goal of this clinical investigation is to evaluate if VES-0-D (an investigational wound gel) works to treat mild to moderate Diabetic Foot Ulcers.
- Trial name
- AIM-DFU (NCT07783087)
- Testing
- VES-0-D wound gel, Standard of Care (Investigator Choice)
- Where
- 8 sites in Belgium
- Volunteers
- 64 people
- Sponsor
- Flen Health